SEARCH:

Candidiasis - Clinical types and Treatment

 Candidiasis is a disease caused by infection with a yeast like fungus, Candida albicans, although other species may also be involved, such as C. tropicalis, C. parapsilosis, C. stellatoidea, C. krusei, C. glabrata, C. pseutropicalis and C. guilliermondii. Candidiasis is the most common opportunistic infection in the world. Its occurrence has surged since the prevalent use of antibiotics, which destroy the normal inhibitory bacterial flora, and immunosuppressive drugs, particularly corticosteroids and cytotoxic drugs. Oral candidiasis or oral thrush usually remain as a localized disease, but on occasion it may show extension to the pharynx or even to the lungs. 

Some specific conditions that may predispose a patient to develop oral candidiasis are:
❍ Factors that alter the immune status of the host
❍ Diabetes mellitus
❍ Corticosteroid therapy/hypoadrenalism
❍ Blood dyscrasias or advanced malignancy
❍ Old age/infancy
❍ Radiation therapy/chemotherapy
❍ HIV infection or other immunodeficiency disorders
❍ Endocrine abnormalities
❍ Hypothyroidism or hypoparathyroidism
❍ Pregnancy

Clinical presentation
Acute pseudomembranous candidiasis:  Pseudomembranous candidiasis is the most common form of oral candidiasis. The most common sites of occurrence include buccal mucosa, dorsal tongue and palate. It is usually seen after antibiotic therapy or immunosuppression. A burning sensation usually
precedes the appearance of soft, creamy white to yellow, elevated plaques, that are easily wiped off from the affected oral tissues and leave an erythematous, eroded, or ulcerated surface which may be tender. Candidiasis may be seen in neonates and among terminally ill patients, particularly in association with serious underlying conditions such as leukemia and other malignancies and in HIV
disease.

Chronic hyperplastic candidiasis: (candida leukoplakia) Hyperplastic candidiasis is seen as chronic, discrete raised lesions that vary from small, palpable translucent whitish areas to large, dense, opaque plaques, hard and rough to touch. The most common sites are the anterior buccal mucosa along the occlusal line, and laterodorsal surfaces of the tongue. The most common appearance is that of asymptomatic white plaques or papules (sometimes against an erythematous background) that are adherent and do not scrape off.

Chronic atrophic (erythematous) candidiasis:  The most common site is the hard palate under a denture
but atrophic candidiasis may also be found on the dorsal tongue and other mucosal surfaces. The most common etiology is poor denture hygiene, and/or continuous denture insertion, but it may also be caused by immunosuppression, xerostomia, or antibiotic therapy.

Median rhomboid glossitis: Median rhomboid glossitis is a form of chronic atrophic candidiasis characterized by an asymptomatic, elongated, erythematous patch of atrophic mucosa of the posterior mid-dorsal surface of the tongue due to a chronic Candida infection. In the past, median rhomboid glossitis was thought to be a developmental defect resulting from a failure of the tuberculum impart to retract before fusion of the lateral processes of the tongue. 

Angular cheilitis (perleche): Clinical appearance is that of red, eroded, fissured lesions which occur bilaterally in the commissures of the lips and are frequently irritating and painful. The most common etiology is loss of vertical occlusal dimension, but it may also be associated with immunosuppression.

Chronic multifocal oral candidiasis: This term has been given to chronic candidal infection that may be seen in multiple oral sites, with various combinations, including angular stomatitis, median rhomboid glossitis and palatal lesions.

Chronic mucocutaneous candidiasis (CMC): It is the term given to the group of rare syndromes, with  definable immune defects, in which there is persistent mucocutaneous candidiasis that responds poorly to topical antifungal therapy.

Treatment: 
Topical versus systemic drugs Topical antifungals are usually the drug of choice for uncomplicated, localized candidiasis in patients with normal immune function. Systemic antifungals are usually indicated in cases of disseminated disease and/or in immunocompromised patients.

Topical antifungal medications: Nystatin is the first specific antifungal agent effective in the treatment of candidiasis.

Nystatin oral suspension 100,000 units/ml; 300 ml: rinse with one teaspoonful (5 ml) for 2 minutes, use q.i.d. (after meals, and at bedtime) and spit out. Patient can be directed to rinse and swallow if there is
pharyngeal involvement.

Amphotericin B - a cornerstone of therapy for systemic fungal infections.
Clotrimazole - most potent topical agent in azole group of antifungals. 10 mg 70 troches; one troche dissolved in mouth five times per day for 14 days.

Systemic antifungal medications 
Ketoconazole tablets, 200 mg 1 tab q.i.d. with a meal or orange juice for 14 days. Ketoconazole is the drug being used in the treatment of chronic mucocutaneous candidiasis and candidiasis
in immunocompromised patients.

Fluconazole tablets, 100 mg, 15 tablets; 2 tablets to start, then 1 tablet q.i.d. for 14 days, oral absorption of fluconazole is rapid and nearly complete within 2 hours.

Itraconazole tablets, 100 mg, 1 tablet b.i.d. with a meal or orange juice for 14 days. This drug has a long half-life and fewer side effects than ketoconazole but is expensive. Its use is contraindicated in liver diseases.

Treatment for chronic atropic candidiasis Application of a thin coat of medicines like nystatin ointment or clotrimazole cream 1% or miconazole cream 2%, ketoconazole cream 2% to entire inner surface of denture after each meal for 14 days usually results in remission. Patient should be instructed to leave dentures out at night and to soak denture in a 1% sodium hypochlorite solution for 15 minutes with thorough rinsing under running water for at least 2 minutes, before bedtime.

Nystatin–triamcinolone acetonide ointment or clotrimazole cream 1% or miconazole cream 2% or ketoconazole cream 2% can be applied to affected areas q.i.d. (after meals, and at bedtime) for 14 days.




Areas anesthetized by the intraoral inferior alveolar nerve block include:

 # Areas anesthetized by the intraoral inferior alveolar nerve block include:
A. The body of the mandible
B. The inferior portion of the ramus
C. Mandibular teeth
D. All of the above



The correct answer is D. All of the above.

Areas Anesthetized by Inferior alveolar nerve block
1. Mandibular teeth to the midline
2. Body of the mandible, inferior portion of the ramus
3. Buccal mucoperiosteum, mucous membrane anterior to the mental foramen (mental nerve)
4. Anterior two thirds of the tongue and floor of the oral cavity (lingual nerve)
5. Lingual soft tissues and periosteum (lingual nerve)

Ref: Handbook of Local Anesthesia, Malamed, 6th Edition, Page 227


For a successful intraoral palatal second divisions nerve block anesthesia, the needle should enter the:

 # For a successful intraoral palatal second divisions nerve block anesthesia, the needle should enter the:
A. Incisive canal
B. Infraalveolar foramen
C. Greater palatine foramen
D. Stylomastoid foramen



The correct answer is C. Greater palatine foramen.

Area of insertion: palatal soft tissue directly over the greater palatine foramen
Target area: the maxillary nerve as it passes through the pterygopalatine fossa; the needle passes through the greater palatine canal to reach the pterygopalatine fossa

Ref: Handbook of Local anesthesia, Malamed, 6th Edition Page 220


The first line of treatment in a patient with syncope due to local anesthesia is administration of:

 # The first line of treatment in a patient with syncope due to local anesthesia is administration of:
A. Oxygen
B. Respiratory stimulant
C. Adrenaline
D. Diazepam



The correct answer is A. Oxygen.

Definitive care after syncopal attack:
-Administer O2
- Monitor vital signs
- Perform additional procedures: Administer aromatic ammonia vaporole; Administer “sugar” (e.g., orange juice, non-diet soft drink)
- Administer atropine if bradycardia persists
- Do not panic!

Reference: Medical Emergencies in the Dental Office, Malamed, 7th edition Page no: 151

What is the fate of nitrous oxide when administered for relative analgesia?

 # What is the fate of nitrous oxide when administered for relative analgesia?
A. Excreted by kidney
B. Detoxified in liver
C. Exhaled by lungs
D. Exhaled by sweat glands



The correct answer is C. Exhaled by lungs.

As the sole agent, N2O (50%) has been used with O2 for dental and obstetric analgesia. It is
nontoxic to liver, kidney and brain. However, prolonged N2O anaesthesia has the potential to
depress bone marrow and cause peripheral neuropathy. Metabolism of N2O does not occur;
it is quickly removed from the body by lungs. It is cheap and commonly used.

Reference: Essentials of Medical Pharmacology, KD Tripathi, Seventh edition page no 378

Hematoma formation after posterior superior alveolar nerve block

 # If hematoma formation occurs after posterior superior alveolar nerve block, it is due to the damage of:
A. Pterygoid venous plexus
B. Small capillaries and arterioles in the region
C. Facial artery
D. Internal maxillary artery



The correct answer is A. Pterygoid venous plexus.

Complications after posterior superior alveolar nerve block
1. Hematoma:
a. This is commonly produced by inserting the needle too far posteriorly into the pterygoid plexus of veins. In addition, the maxillary artery may be perforated. Use of a short needle minimizes the risk of pterygoid plexus puncture.

b. A visible intraoral hematoma develops within several minutes, usually noted in the buccal tissues of the mandibular region.
(1) There is no easily accessible intraoral area to which pressure can be applied to stop the hemorrhage.
(2) Bleeding continues until the pressure of extravascular blood is equal to or greater than that of intravascular blood.

Reference: Handbook of Local Anesthesia, Malamed, 6th Edition, Page 195

AIIMS NOVEMBER 2015 MDS PAST ENTRANCE EXAM MCQs


# Medial dislocation of fractured condyle in subcondylar fracrure is caused by:
A. Medial pterygoid
B. Lateral pterygoid
C. Masseter
D. Buccinator

# A dental surgeon has recoverd from Hepatitis B by 3 months rest. His laboratory findings are normal but he is not allowed to attend patients as per medical board as he is:
A. healthy carrier
B. active carrier
C. convalescent carrier
D. paradoxical carrier